Results 41 to 50 of about 33,952 (165)

Codon deoptimization of multispecific biologics reduces mispairing during transient mammalian protein expression

Frontiers in Bioengineering and Biotechnology
IntroductionCodon optimization is utilized in biologics design to maximize protein expression. Selecting the host organism’s most frequently used codons for each amino acid can significantly enhance recombinant protein expression yields.
Timothy Z. Chang, Weijun Ma, Jane Guo, Jiali Hu, Kalie Mix, Yi Tang, Karen Wong, Eva Bric-Furlong, Amanda Lennon, Brian Hall, Dietmar Hoffmann   +10 more
doaj   +1 more source

Elranatamab in Heavily Pretreated Triple-class Refractory Multiple Myeloma: A Single-center Experience

Acta Haematologica Oncologica Turcica
Aim: This study aimed to assess the real-world performance of elranatamab in terms of its effectiveness, safety, and tolerability among patients diagnosed with triple-class refractory-multiple myeloma (TCR-MM) who have undergone extensive prior treatment.
Ant Uzay
doaj   +1 more source

The Role of Tumor Microenvironment and Targeted Therapy in Chronic Lymphocytic Leukemia

Current Issues in Molecular Biology
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. It is characterized by the clonal proliferation of mature B cells. The tumor microenvironment (TME) seems to play a crucial role in the survival and proliferation of tumor cells ...
Khalil Saleh, Ahmadreza Arbab, Nadine Khalife, Rita Khoury, Rebecca Ibrahim, Mohamad Ali Hachem, Cynthia Khalil, Cendrella Bou Orm, Joud Sawan, Geoffroy Lafarge, Nohad Masri, Zamzam Tikriti, Claude Chahine, Axel Le Cesne   +13 more
doaj   +1 more source

Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific

Cell Reports Medicine
Summary: Metastatic uveal melanoma is an aggressive disease with poor outcome, which is refractory to immune checkpoint inhibitors. A T cell receptor (TCR)-based CD3 bispecific, tebentafusp, delivers clinical benefit in patients with metastatic uveal ...
Joseph J. Sacco, Peter Kirk, Emma Leach, Alexander N. Shoushtari, Richard D. Carvajal, Camille Britton-Rivet, Sophie Khakoo, Laura Collins, Luis de la Cruz-Merino, Zeynep Eroglu, Alexandra P. Ikeguchi, Paul Nathan, Omid Hamid, Marcus O. Butler, Sarah Stanhope, Koustubh Ranade, Takami Sato   +16 more
doaj   +1 more source

Augmented emicizumab-driven coagulation potential in hemophilia A state by in vitro and in vivo supplementation of combined factors IX and X

Research and Practice in Thrombosis and Haemostasis
Background: Persons with hemophilia A (HA) and inhibitors undergoing emicizumab prophylaxis require bypassing agents when breakthrough bleeding occurs.
Mitsumasa Osuna, Yuto Nakajima, Eisuke Takami, Hirotoshi Nakano, Keiji Nogami   +4 more
doaj   +1 more source

Bispecific antibodies that engage pIgR enrich in mucosa in cynomolgus monkeys

mAbs
Therapeutic antibodies have limited access to barrier‑protected compartments such as the brain, lung and gastric mucosa, and kidney lumen, constraining their effectiveness in many diseases.
Kelsie Marks, Nirav Shah, Ly Pham, Jun Chen, Ian White, Krista Burke, Peter Garrett, Mathieu Marella, Prathap Nagaraja Shastri, Brian Geist, Partha Chowdhury, Vinicius Carreira, Wan Cheung Cheung, Adam Zwolak   +13 more
doaj   +1 more source

Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions

mAbs
The development of bispecific antibodies that bind at least two different targets relies on bringing together multiple binding domains with different binding properties and biophysical characteristics to produce a drug-like therapeutic.
Michael Mullin, James McClory, Winston Haynes, Justin Grace, Nathan Robertson, Gino van Heeke   +5 more
doaj   +1 more source

IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release

mAbs
T cell engagers (TCEs) are becoming an integral class of biological therapeutic owing to their highly potent ability to eradicate cancer cells. Nevertheless, the widespread utility of classical CD3-targeted TCEs has been limited by narrow therapeutic ...
John S. Schardt, Even Walseng, Kim Le, Chunning Yang, Pooja Shah, Ying Fu, Kausar Alam, Cathryn R. Kelton, Yu Gu, Fengying Huang, Jia Lin, Wenhai Liu, Andrew Dippel, Hanzhi Zhang, Kathy Mulgrew, Stacy Pryts, Vijaykumar Chennupati, Hung-Chang Chen, Jessica Denham, Xiaoru Chen, Pallab Pradhan, Yuling Wu, Colin Hardman, Chihao Zhao, Michael Kierny, Yang Song, Simon J. Dovedi, Saso Cemerski, Yariv Mazor   +28 more
doaj   +1 more source

Developability considerations for bispecific and multispecific antibodies

mAbs
Bispecific antibodies (bsAb) and multispecific antibodies (msAb) encompass a diverse variety of formats that can concurrently bind multiple epitopes, unlocking mechanisms to address previously difficult-to-treat or incurable diseases. Early assessment of
Alaa Amash, Gesa Volkers, Patrick Farber, Daniel Griffin, K. Shawn Davison, Allison Goodman, Raffi Tonikian, Aaron Yamniuk, Bryan Barnhart, Tim Jacobs   +9 more
doaj   +1 more source

Lineage switch of adult B-cell acute lymphoblastic leukaemia to acute myeloid leukaemia following B-cell-directed therapy

European Journal of Case Reports in Internal Medicine
Background: Blinatumomab and inotuzumab ozogamicin (InO) are B-cell targeted agents used in the frontline and relapsed/refractory treatment of B-cell acute lymphoblastic leukaemia (B-ALL).
Oscar F. Borja-Montes, Darrell D. Horton, Alejandro Toro-Pedroza, Tomas Escobar-Gil, Daniel Babu, Charles Foucar, Ala Ebaid   +6 more
doaj   +1 more source